^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Genito-urinary Cancer

    6h
    Endoplasmic reticulum stress-related genes as prognostic and immunogenic biomarkers in prostate cancer. (PubMed, Eur J Med Res)
    We identified ERLIN2 and CDK5RAP3 as ERS-related genes with important prognostic and immunologic values, and classified patients between high- and low-risk subgroups, which provided new prognostic markers, immunotherapeutic targets, and basis for prognostic assessments.
    Journal • IO biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated) • SPOP (Speckle Type BTB/POZ Protein)
    9h
    THOR: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (clinicaltrials.gov)
    P3, N=629, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2024 --> Nov 2026
    Trial completion date • Metastases
    |
    Keytruda (pembrolizumab) • docetaxel • Balversa (erdafitinib) • Javlor (vinflunine)
    9h
    Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=90, Enrolling by invitation, University of Texas Southwestern Medical Center | Recruiting --> Enrolling by invitation
    Enrollment status • Metastases
    10h
    18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    10h
    Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans (clinicaltrials.gov)
    P=N/A, N=6, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=95 --> 6
    Enrollment closed • Enrollment change
    11h
    SunRISe-5: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (clinicaltrials.gov)
    P3, N=250, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mitomycin • GemRIS (gemcitabine-releasing intravesical system)
    11h
    Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy (clinicaltrials.gov)
    P=N/A, N=5, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    11h
    AZGP1 deficiency promotes angiogenesis in prostate cancer. (PubMed, J Transl Med)
    AZGP1 is a negative regulator of angiogenesis, such that loss of AZGP1 promotes angiogenesis in prostate cancer. AZGP1 likely exerts heterotypical effects on cells in the tumor microenvironment, such as stromal and endothelial cells. This study sheds light on the anti-angiogenic characteristics of AZGP1 in the prostate and provides a rationale to target AZGP1 to inhibit prostate cancer progression.
    Journal
    |
    ANXA1 (Annexin A1) • MMP9 (Matrix metallopeptidase 9) • SERPINE1 (Serpin Family E Member 1) • HSPB1 (Heat shock 27kDa protein 1) • AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
    11h
    Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer. (PubMed, Mol Cancer)
    Moreover, our findings first emphasized the functional importance of IGF2BPs as epigenetic R-loop readers in transcriptional genetic regulation and cancer biology. In addition, our research provides a novel RBM15/IGF2BPs/DNMT1 trans-omics regulation m6A axis, indicating the new crosstalk between RNA m6A methylation and DNA methylation in prostate cancer.
    Journal • Metastases
    |
    DNMT1 (DNA methyltransferase 1) • RBM15 (RNA Binding Motif Protein 15)
    |
    docetaxel
    11h
    Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma. (PubMed, BMC Urol)
    LRG1 served as a serum marker associated with inflammation, indicated by CRP, anemia, hypercalcemia, and malignant potential in ccRCC. Clinically, serum LRG1 levels may assist in differentiating ccRCC from non-ccRCC with excellent diagnostic accuracy.
    Journal
    |
    CRP (C-reactive protein)
    11h
    CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling. (PubMed, Cancer Cell Int)
    Taken together, our results demonstrate the significant role of CDCA5 in ccRCC progression. The findings may provide insights for the development of new treatment strategies targeting CDCA5 for ccRCC patients.
    Journal
    |
    EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
    |
    Sutent (sunitinib)
    11h
    Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases. (PubMed, Sci Rep)
    PDCD1 and TIGIT encode immune checkpoint receptors involved in the regulation of Tregs function. Our study sets the direction for further functional research regarding a probable role of LOY in intensifying features related to the suppressive phenotype of Tregs in TME and consequently a possible influence on immunotherapy response in CRC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • IKZF2 (IKAROS family zinc finger 2)
    11h
    MMPs-related risk model identification and SAA1 promotes clear cell renal cell carcinoma migration via ERK-AP1-MMPs axis. (PubMed, Sci Rep)
    In conclusion, our study has explored the potential value of the MMP family as prognostic markers for ccRCC and as guides for medication regimens. Additionally, we have identified SAA1 as a crucial factor in the migration of ccRCC.
    Journal
    |
    SAA1 (Serum Amyloid A1)
    11h
    PMPRC: Precision Medicine in the Prostate Cancer Care Pathway (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Dec 2025 --> Dec 2030
    Trial completion date
    11h
    REASSURE: Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=1474, Active, not recruiting, Bayer | Trial completion date: Feb 2025 --> Oct 2024
    Trial completion date • Metastases
    |
    Xofigo (radium Ra-223 dichloride)
    11h
    MoonRISe-1: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (clinicaltrials.gov)
    P3, N=540, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • erdafitinib intravesical delivery system (TAR-210)
    12h
    Part I: prostate cancer detection, artificial intelligence for prostate cancer and how we measure diagnostic performance: a comprehensive review. (PubMed, Curr Probl Diagn Radiol)
    Finally, this work explores the need for appropriately enriched investigational datasets and proper ground truth, and provides guidance on how to best conduct AI prostate MRI studies. Published in parallel, a clinical study applying this suggested study design was applied to review and report a multiple-reader multiple-case clinical study of 150 bi-parametric prostate MRI studies across nine readers, measuring physician performance both with and without the use of a recently FDA cleared Artificial Intelligence software.1.
    Review • Journal
    |
    Decipher Prostate Cancer Test
    12h
    Exposure to environmental pollutants and genetic variants related to oxidative stress and xenobiotic metabolism - Association with prostate cancer. (PubMed, Environ Toxicol Pharmacol)
    High serum PSA levels were associated with a greater risk of PCa, while physical exercise appears to exert a protective effect against its development. In addition, elevated urinary levels of certain organic pollutants, such as benzo(a)pyrene (BaP), bisphenol A (BPA), and ethyl-paraben (EPB), were associated with an increased risk of PCa.
    Journal
    |
    GSTP1 (Glutathione S-transferase pi 1) • GSTM1 (Glutathione S-transferase mu 1) • XRCC1 (X-Ray Repair Cross Complementing 1) • SOD2 (Superoxide Dismutase 2)
    13h
    NeoADT-TULSA: Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Turku University Hospital | Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> Dec 2025
    Enrollment open • Trial initiation date • Trial primary completion date
    |
    Firmagon (degarelix)
    13h
    PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors. (PubMed, BMC Urol)
    It cannot be fully excluded that the strong statistical link between PD-L1 status and favorable histological tumor features as well as better prognosis could influence the outcome of studies evaluating CPIs in muscle-invasive urothelial carcinoma.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Inflammatory cell
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    13h
    Mechanism of single-stranded DNA annealing by RAD52-RPA complex. (PubMed, Nature)
    RPA associates with RAD52 at the site of ring opening with critical interactions occurring between the RPA-interacting domain of RAD52 and the winged helix domain of RPA2. Our studies provide structural snapshots throughout the annealing process and define the molecular mechanism of ssDNA annealing by the RAD52-RPA complex.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • RAD52 (RAD52 Homolog DNA Repair Protein) • RPA2 (Replication Protein A2)
    13h
    Pan-Cancer Analysis Shows that KIFC2 is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Bladder Cancer. (PubMed, Mol Biotechnol)
    The differences in the expression of KIFC2 in the bladder cancer tissues (14 pairs) were statistically significant. The pan-cancer analysis in this study revealed the multifunctionality of KIFC2 in a variety of tumors, indicating a possible prognostic predictor and potential therapeutic target for tumors.
    Journal • Tumor mutational burden • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    14h
    Estrogen receptor beta expression and role in cancers. (PubMed, J Steroid Biochem Mol Biol)
    The use of nonspecific antibodies has contributed to the confusion, and this review delves into ERβ's controversial role in cancer and focuses on tumor expression that can be supported by non-antibody-dependent assays. We discuss its expression at the transcript level and focus on its potential role in lymphoma, granulosa cell tumor, testicular, and adrenal cancers, emphasizing recent findings and the complexities that necessitate further research.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER expression
    14h
    A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma. (PubMed, Cancer Immunol Immunother)
    This study suggests that autologous RAK cell immunotherapy is safe and has clinical activity in previously treated mRCC patients. The improvement in peripheral blood immune profiling after RAK cell infusion highlights its potential as a cancer treatment. Further investigation is necessary to understand its clinical utility.
    P1 data • Clinical Trial,Phase I • Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    18h
    NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. (PubMed, J Clin Oncol)
    NECTIN4 amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.
    Journal • Metastases
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    NECTIN4 expression
    |
    Padcev (enfortumab vedotin-ejfv)
    18h
    ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. (PubMed, Cancer Res)
    Conversely, elevated ACSM1/3 activity enabled prostate cancer cells to survive toxic levels of medium chain fatty acids and promoted resistance to ferroptosis-inducing drugs and AR antagonists. Collectively, this study reveals a tumor-promoting function for medium chain acyl-CoA synthetases and positions ACSM1 and ACSM3 as key players in prostate cancer progression and therapy resistance.
    Journal
    |
    ACSM3 (Acyl-CoA Synthetase Medium Chain Family Member 3) • ACSM1 (Acyl-CoA Synthetase Medium Chain Family Member 1)
    18h
    Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer (PubMed, Lakartidningen)
    Unfortunately, methods within clinical routine today do not allow molecular subclassification of prostate cancer. To enable comparison of the most promising treatment-predictive biomarkers and to evaluate the health economic value of implementing such precision medicine for prostate cancer, a prospective study is being planned as a joint initiative in Sweden that aims to evaluate and validate biomarkers and to establish a study platform for adaptive biomarker-driven clinical trials (sprintr.se).
    Review • Journal • Metastases
    |
    AR (Androgen receptor) • KLK3 (Kallikrein-related peptidase 3)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Prolaris®
    18h
    Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery. (PubMed, World J Urol)
    The assessment of AP, CEA, LDH, and NSE before salvage PSMA-RGS showed no prognostic impact. Further studies are needed to identify possible predictors that will optimize patient selection for salvage PSMA-RGS.
    Retrospective data • Journal • Surgery
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    19h
    Study on the Role and Mechanism of SLC3A2 in Tumor-Associated Macrophage Polarization and Bladder Cancer Cells Growth. (PubMed, Technol Cancer Res Treat)
    However, the impact of SLC3A2 interference on cell proliferation and macrophage polarization was impeded by ferroptosis inhibitors. Interference with SLC3A2 inhibited the growth of BLCA cells and the polarization of tumor-associated macrophages by promoting ferroptosis in BLCA cells.
    Journal
    |
    SLC3A2 (Solute Carrier Family 3 Member 2) • GPX4 (Glutathione Peroxidase 4) • TFRC • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    SLC3A2 expression • SLC7A11 expression
    20h
    The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism. (PubMed, Cancer Sci)
    Furthermore, an in vivo study showed that JPH203 inhibited the proliferation of C4-2 cells in a castration environment. The results of this study indicate that JPH203 may exert its antitumor effect in CRPC cells via mTOR and CD24.
    Journal
    |
    CD24 (CD24 Molecule)
    |
    nanvuranlat (JPH203)
    20h
    Acoustic Enrichment of Heterogeneous Circulating Tumor Cells and Clusters from Metastatic Prostate Cancer Patients. (PubMed, Anal Chem)
    Our preliminary data indicate that acoustophoresis provides excellent possibilities to detect and characterize CTC clusters as a putative marker of metastatic disease and outcomes. Moreover, acoustophoresis enables the sensitive label-free enrichment of cells with epithelial phenotypes in blood and offers opportunities to detect and characterize CTCs undergoing epithelial-to-mesenchymal transitioning and lineage plasticity.
    Journal • Circulating tumor cells • Tumor cell • Metastases
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    CELLSEARCH®
    21h
    Identification of ALDOB as a novel prognostic biomarker in kidney clear cell renal cell carcinoma. (PubMed, Heliyon)
    In addition, we have also discovered the effect of ALDOB in previous studies on other cancer types. Finally, we concluded that ALDOB may have potential reference value for immunotherapy and can also be used as an independent predictor of prognosis in KIRC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ALDOB (Aldolase, Fructose-Bisphosphate B)
    21h
    AURKA promotes renal cell carcinoma progression via regulation of CCNB1 transcription. (PubMed, Heliyon)
    CCNB1 expression was essential for AURKA-induced RCC progression. Collectively, our results suggested that AURKA plays an important role in development of RCC via regulating CCNB1 transcription.
    Journal
    |
    AURKA (Aurora kinase A) • CCNB1 (Cyclin B1) • E2F1 (E2F transcription factor 1)
    |
    AURKA expression
    21h
    Undiagnosed RASopathies in infertile men. (PubMed, Front Endocrinol (Lausanne))
    Undiagnosed RASopathies were especially enriched among patients with a history of cryptorchidism. Given the relationship between RASopathies and other conditions, infertile men found to have this molecular diagnosis should be evaluated for known RASopathy-linked health concerns, including specific rare malignancies.
    Journal
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    1d
    Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Xiao X. Wei, MD | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OncoPanel™ Assay
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    1d
    Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov)
    P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world • Metastases
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • leuprolide acetate for depot suspension
    1d
    Solar-Recur: Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (clinicaltrials.gov)
    P3, N=200, Recruiting, Curium US LLC | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
    Trial completion date • Trial primary completion date
    1d
    Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, University of Wuerzburg | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    1d
    Solar-Stage: Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (clinicaltrials.gov)
    P3, N=323, Recruiting, Curium US LLC | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=388, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    Cabometyx (cabozantinib tablet)
    1d
    TRAVELER: A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=150, Terminated, Pfizer | Trial completion date: Oct 2023 --> Jun 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Jun 2023; The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    Bavencio (avelumab)